ARTICLE | Emerging Company Profile
Metal smithing
How Forge's metal-binding chemistry can tackle tough metalloenzyme targets
August 22, 2016 7:00 AM UTC
Forge Therapeutics Inc. is using a library of metal-binding pharmacophores that avoid known pharmacologic and safety liabilities of a common metal-binding motif to create inhibitors of metalloenzymes, starting with notoriously tough targets.
Forge's lead program is a broad-spectrum Gram-negative antibiotic targeting UDP-3-O-[3-hydroxymyristoyl] N-acetylglucosamine deacetylase (LpxC)...